Dianthus Therapeutics (NASDAQ:DNTH) Hits New 1-Year Low – What’s Next?

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) hit a new 52-week low during mid-day trading on Tuesday . The company traded as low as $18.13 and last traded at $19.17, with a volume of 28891 shares changing hands. The stock had previously closed at $19.62.

Analysts Set New Price Targets

A number of research firms recently issued reports on DNTH. Raymond James upgraded Dianthus Therapeutics to a “moderate buy” rating in a research note on Thursday, December 12th. Oppenheimer increased their price target on shares of Dianthus Therapeutics from $48.00 to $52.00 and gave the stock an “outperform” rating in a research note on Monday, November 11th. TD Cowen started coverage on shares of Dianthus Therapeutics in a research note on Friday, December 20th. They issued a “buy” rating on the stock. Finally, HC Wainwright reiterated a “buy” rating and set a $40.00 target price on shares of Dianthus Therapeutics in a research note on Monday, November 11th. Seven analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Buy” and an average price target of $46.83.

Dianthus Therapeutics Stock Performance

The company has a market cap of $587.32 million, a price-to-earnings ratio of -7.91 and a beta of 1.72. The company has a 50-day simple moving average of $22.59 and a 200-day simple moving average of $25.20.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the business. FMR LLC boosted its position in shares of Dianthus Therapeutics by 0.8% during the 4th quarter. FMR LLC now owns 4,439,281 shares of the company’s stock worth $96,776,000 after purchasing an additional 36,133 shares in the last quarter. Octagon Capital Advisors LP boosted its holdings in Dianthus Therapeutics by 20.8% during the fourth quarter. Octagon Capital Advisors LP now owns 2,110,167 shares of the company’s stock worth $46,002,000 after buying an additional 363,500 shares in the last quarter. TCG Crossover Management LLC acquired a new position in Dianthus Therapeutics during the fourth quarter worth about $32,735,000. Braidwell LP increased its holdings in Dianthus Therapeutics by 144.4% in the fourth quarter. Braidwell LP now owns 1,206,589 shares of the company’s stock valued at $26,304,000 after buying an additional 712,902 shares in the last quarter. Finally, Alliancebernstein L.P. lifted its position in shares of Dianthus Therapeutics by 13.4% during the 4th quarter. Alliancebernstein L.P. now owns 1,159,776 shares of the company’s stock valued at $25,283,000 after acquiring an additional 136,633 shares during the period. Institutional investors and hedge funds own 47.53% of the company’s stock.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.